AMGN

Amgen (AMGN) Stock Sees Modest Fair Value Lift As Analysts Weigh Pipeline Risks

Amgen’s updated analyst model now points to a fair value price target of US$388.03, compared with the prior US$371.93. This provides a slightly higher anchor for how the stock is being valued today. This shift comes as r

A Failed Cholesterol Drug Raises the Stakes for Amgen (AMGN) and Eli Lilly (LLY) Too

On September 8, 2026, CNBC reported that Novartis’ failed pelacarsen trial has raised the stakes for rival experimental cholesterol drugs from Amgen Inc. (NASDAQ:AMGN) and Eli Lilly and Company (NYSE:LLY), both of which

Amgen Stock Fell 10% in a Day on a Drug It Doesn’t Own. Is It Time to Buy AMGN?

Key Stats for Amgen StockCurrent Price: $375. 65Target Price (Mid): ~$495Street Target: ~$388Potential Total Return: ~32%Annualized IRR: ~6.

4 Defensive Stocks to Take Refuge in as Consumer Sentiment Plummets

ADM, COCO, AMGN and CNC offer defensive exposure as inflation, oil prices and weak consumer sentiment fuel market volatility.

Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

What Would It Take For Eli Lilly Stock To Keep Climbing?

Eli Lilly (LLY) trades near $1,150, up about 52% over the past year, and is now worth more than a trillion dollars. At that size the easy read is that the big money has been made. But Lilly has barely started selling Fou

Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects?

Bristol Myers' Sotyktu delivers durable PsA responses for two years, supporting its growth strategy as competition intensifies.

Why This Biotech Stock Just Got a Rare Double Upgrade

The biotech company’s stock rises after Barclays gives it a double upgrade, citing confidence in upcoming FDA approvals.